HUE052210T2 - Egy TLR7 agonista trifluoracetát sója és annak B kristályos formája, elõállítási eljárások és alkalmazások - Google Patents

Egy TLR7 agonista trifluoracetát sója és annak B kristályos formája, elõállítási eljárások és alkalmazások

Info

Publication number
HUE052210T2
HUE052210T2 HUE17747007A HUE17747007A HUE052210T2 HU E052210 T2 HUE052210 T2 HU E052210T2 HU E17747007 A HUE17747007 A HU E17747007A HU E17747007 A HUE17747007 A HU E17747007A HU E052210 T2 HUE052210 T2 HU E052210T2
Authority
HU
Hungary
Prior art keywords
crystalline form
preparation methods
trifluoroacetate salt
tlr7 agonist
tlr7
Prior art date
Application number
HUE17747007A
Other languages
English (en)
Inventor
Zhaozhong Ding
Fei Sun
Yinghu Hu
Yilong Zhou
Zheng Wang
Rui Zhao
Ling Yang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of HUE052210T2 publication Critical patent/HUE052210T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
HUE17747007A 2016-02-05 2017-02-04 Egy TLR7 agonista trifluoracetát sója és annak B kristályos formája, elõállítási eljárások és alkalmazások HUE052210T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610081899.3A CN107043377A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途

Publications (1)

Publication Number Publication Date
HUE052210T2 true HUE052210T2 (hu) 2021-04-28

Family

ID=59500539

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17747007A HUE052210T2 (hu) 2016-02-05 2017-02-04 Egy TLR7 agonista trifluoracetát sója és annak B kristályos formája, elõállítási eljárások és alkalmazások

Country Status (23)

Country Link
US (1) US10683296B2 (hu)
EP (1) EP3412674B1 (hu)
JP (1) JP6877450B2 (hu)
KR (1) KR102393281B1 (hu)
CN (2) CN107043377A (hu)
AR (1) AR107550A1 (hu)
AU (1) AU2017214135B2 (hu)
CA (1) CA3013521C (hu)
CL (1) CL2018002101A1 (hu)
DK (1) DK3412674T3 (hu)
EA (1) EA037048B1 (hu)
ES (1) ES2834304T3 (hu)
HK (1) HK1259182A1 (hu)
HU (1) HUE052210T2 (hu)
IL (1) IL260981B (hu)
MX (1) MX2018009503A (hu)
NZ (1) NZ745023A (hu)
PH (1) PH12018501641B1 (hu)
SG (1) SG11201806688QA (hu)
TW (1) TWI778952B (hu)
UA (1) UA121276C2 (hu)
WO (1) WO2017133687A1 (hu)
ZA (1) ZA201805240B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
KR20210013183A (ko) * 2018-05-25 2021-02-03 치아타이 티안큉 파마수티컬 그룹 주식회사 Tlr7 작용제 및 폐암을 치료하기 위한 이의 약학 조합물
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
US20230100429A1 (en) 2020-03-02 2023-03-30 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
CN116056725A (zh) 2020-08-04 2023-05-02 蛋白科技先鋒 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途
JP2023536945A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 動力学的に作用するアジュバントアンサンブル
AU2023206890A1 (en) 2022-01-12 2024-08-22 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
EA021377B9 (ru) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
EP2670244B1 (en) 2011-02-04 2018-04-11 Duquesne University of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2800569B1 (en) 2012-01-05 2018-07-25 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
NZ705589A (en) * 2012-10-10 2019-05-31 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
EP2922550B1 (en) * 2012-11-20 2017-04-19 Glaxosmithkline LLC Novel compounds
NZ724878A (en) * 2014-05-01 2019-03-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
CR20160512A (es) * 2014-05-01 2016-12-21 Novartis Ag Compuestos y composiciones como agonistas del receptor tipo toll 7
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
EA032824B1 (ru) 2014-08-15 2019-07-31 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂

Also Published As

Publication number Publication date
EP3412674A1 (en) 2018-12-12
NZ745023A (en) 2022-09-30
US20190031666A1 (en) 2019-01-31
KR20180104118A (ko) 2018-09-19
CN107043377A (zh) 2017-08-15
CN108602833B (zh) 2020-07-28
PH12018501641A1 (en) 2019-06-03
JP2019504103A (ja) 2019-02-14
EA201891772A1 (ru) 2019-01-31
US10683296B2 (en) 2020-06-16
PH12018501641B1 (en) 2019-06-03
SG11201806688QA (en) 2018-09-27
KR102393281B1 (ko) 2022-05-02
CL2018002101A1 (es) 2018-12-07
BR112018015878A2 (pt) 2018-12-26
TWI778952B (zh) 2022-10-01
AU2017214135B2 (en) 2020-08-13
CA3013521C (en) 2022-07-12
JP6877450B2 (ja) 2021-05-26
CN108602833A (zh) 2018-09-28
AR107550A1 (es) 2018-05-09
CA3013521A1 (en) 2017-08-10
DK3412674T3 (da) 2020-11-09
ZA201805240B (en) 2024-09-25
EP3412674B1 (en) 2020-09-16
IL260981B (en) 2022-05-01
HK1259182A1 (zh) 2019-11-29
TW201728591A (zh) 2017-08-16
MX2018009503A (es) 2018-12-11
EP3412674A4 (en) 2019-07-17
AU2017214135A1 (en) 2018-08-23
WO2017133687A1 (zh) 2017-08-10
EA037048B1 (ru) 2021-01-29
UA121276C2 (uk) 2020-04-27
ES2834304T3 (es) 2021-06-17

Similar Documents

Publication Publication Date Title
HUE052210T2 (hu) Egy TLR7 agonista trifluoracetát sója és annak B kristályos formája, elõállítási eljárások és alkalmazások
HK1259170A1 (zh) 一種tlr7激動劑的晶型a、其製備方法和用途
HK1259175A1 (zh) 一種tlr7激動劑的馬來酸鹽、其晶型c、晶型d、晶型e及其製備方法和用途
HUE052925T2 (hu) Amid származékok és azok gyógyászatilag elfogadott sói, elõállítási módszere és gyógyászati alkalmazása
PT3580219T (pt) Processo para a preparação de remimazolam e formas de estado sólido de sais de remimazolam
HK1231459A1 (zh) 類胡蘿蔔素衍生物、其藥學上可接受的鹽或者其藥學上可接受的酯類或酰胺類
HUE050782T2 (hu) Eljárás Carboprost és trometamin sójának elõállítására
SG11201608372PA (en) Irinotecan hydrochloride composite phospholipid composition, preparation method and use thereof
IL253186B (en) A new crystalline form of a benzaimidazole derivative and a method for its preparation
IL254530A0 (en) Preparation method of crystalline form a of pci-32765
EP3235851A4 (en) Nylon salt and preparation method therefor
ZA201704743B (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
DK3377049T3 (en) Crystalline forms of tapentadol salts and process for preparation thereof
PL3327012T3 (pl) Krystaliczne postacie bilastyny i sposoby ich wytwarzania
IL271233A (en) Quinolinicyclohexylpropanamide-modified compounds and improved methods for their preparation
EP3369725A4 (en) PHARMACEUTICAL SALT DERIVED FROM POLYAMINE, PROCESS FOR PREPARING SAME AND USE THEREOF
ME03727B (me) Zamjena za so i njena primena
IL254597A0 (en) Crystalline form of ahu377, method for its preparation and use
IL246835A0 (en) Improved process for the preparation of trazodone and its hydrochloride salt
EP3409662A4 (en) NOVEL CONNECTION AND PHARMACEUTICALLY COMPATIBLE SALT OF WHICH
EP3479829A4 (en) MANGIFERIN-6-O-CALCIUM SALTS AND PRODUCTION METHOD AND USE THEREOF
HK1248213A1 (zh) Abexinostat 甲苯磺酸鹽及相關的晶體形式的製備方法